Reuters logo
BRIEF-AcelRx Pharmaceuticals says presents results from Phase 3 study of ARX-04
May 26, 2016 / 11:27 AM / in 2 years

BRIEF-AcelRx Pharmaceuticals says presents results from Phase 3 study of ARX-04

May 26 (Reuters) - Acelrx Pharmaceuticals -

* AcelRx pharmaceuticals inc says co presents results from phase 3 study of ARX-04 following ambulatory abdominal surgeries at Euroanaesthesia

* ARX-04 was well tolerated in trial, with nausea, headache and vomiting being most common treatment-emergent adverse events reported Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below